Market-View-Feature-Image

View on market: Stay Cautious, be with quality business:

Stocks in Asia rose on Monday after strong U.S. employment report on Friday and post-election rally in Japan. The possibility of more Covid curbs in China could, however, dampen sentiment. Japan shares climbed 1.5%, as ruling coalition expanded its majority in an upper house election. US and European equity futures fell while crude oil was volatile around $105 per barrel. At 6:40 am, the Singapore-traded SGX Nifty — an early barometer of India’s benchmark Nifty 50 — fell 0.13% to 16,206.50. Elsewhere, the pound fell as the race to replace Boris Johnson as UK premier heats up.

Economic Calendar:

  • INR: WPI Inflation 14th July 2022.
  • INR: IIP Data 12th July 2022.
  • USD: OPEC Monthly Report 12th July, 2022.
  • USD: Core CPI 13th July, 2022.

Q1FY23 Result Today: TCS

Tata Consultancy Services Q1 FY23 (Consolidated, QoQ) Revenue up 4.28% at Rs 52,758 crore Vs Rs 50,591 crore (Bloomberg Estimate: Rs 5 2,473.5 crore) EBIT fell 3.5% at Rs 12,186 crore Vs Rs 12,628 crore (Bloomberg Estimate: Rs 12,413) EBIT margin 23.1% Vs 24.96% (Bloomberg Estimate: 24%) Net profit fell 4.5% at Rs 9,478 crore Vs Rs 9,926 crore (Bloomberg Estimate: Rs 9,908-crore) Attrition inched up to 19.7% Vs 17.4% Declared interim dividend of Rs 8 per share of face value of Rs 1 each

MMTC Q4 FY22 (Consolidated, QoQ) Revenue fell 3% to at Rs 2,255.59 crore Vs Rs 2320.63 crore EBITDA Rs 512.52 crore Vs negative Rs 19.38 crore EBITDA margin 22.72% Vs -0.84% Net profit of Rs 118.38 crore Vs net loss of Rs 73.89 crore

Brokerage Radar:

CLSA ON REAL ESTATE: Upgrade Oberoi to O-P from U-P, TP Rs 925 Top buys– DLF & Prestige Housing sales & office leasing momentum moderated in 1QFY23 post strong growth in 2HFY22, driven by a slowdown in new supply & seasonality, yet do not see risk to growth in FY23.

JEFFERIES ON AVENUE SUPERMART: Hold, TP Raised to Rs 3900 1Q EBITDA beat est on better gross margin, which were at a 12-qtr high, pushing up EBITDA margin to near-record highs. Mix improved QoQ, but is yet to fully recover 3Y rev & EBITDA CAGR strong at 19%.

CITI ON TCS: Sell, TP Cut to Rs 3015 Inline Revs; Margins miss; TTM TCV +6% yoy With consensus FY23E/FY24E EBIT margins at 25%/25.5% (Citi: 23.7%/23.4%), see downgrades ahead.

NOMURA ON TCS: Reduce, TP Rs 2910 Facing brunt of weakening growth and margin headwinds Order book showing signs of flattening 1QFY23 results miss on all fronts Growth to lag Infosys, lower FY23-24F EPS by 1.4-2.5%.

International Markets:

U.S & Europe:

Particulars      08th June    Chg Chg(%)
Nasdaq 11,635.31 13.96 0.12
Dow 31338.15 -46.40 -0.15
FTSE 7,196.24 7.16 0.1
CAC 6,033.13 26.43 0.44
DAX 13,015.23 172.01 1.34
Dow Fut.* 31204.5 -133.7 -0.43

Asian markets:

Particulars    09th July    Chg. Chg(%)
SGX Nifty 16,118.50 -109 -0.67
Nikkei 26,787.00 269.81 1.02
Straits Times 3,131.26 1.86 0.06
Hang Seng 21,192.53 -533.25 -2.45
Shanghai 3,314.52 -41.56 -1.24

ADR Watch:

Particulars     08th June Chg. Chg.(%)
Dr Reddy 55.84 0.57 1.03
HDFC Bank 59.76 0.29 0.49
ICICI Bank 19.25 0.2 1.05
Infosys 19.06 -0.1 -0.52
Tata Motor 27.9 0.2 0.72
Wipro 5.26 -0.2 -3.66

Commodities & Currency

Particulars Current Price Chg(%)
USD/INR 79.25 0.09
Brent 106.38  -0.60
Gold 1740.00  -0.13
Silver 19.242 -0.03

FIIs & DII:

Particulars   07th June    07th June
FIIs -109.31                    -925.22                   
DIIs  34.61  980.59

News Update:

HDFC/HDFC Bank: The company received approval from Pension Fund Regulatory and Development Authority for the scheme of merger with HDFC Bank. The scheme is yet to receive approval from Competition Commission of India, the National Company Law Tribunal and company’s shareholders and creditors.

CCL Products: The company has forayed into plant-based meat products in India through the launch of its brand Continental Greenbird.

Dr Reddy’s: The company has launched Fesoterodine Fumarate rxtended-release tablets, a therapeutic generic equivalent to Toviaz, in the U.S. market.

Hindustan Aeronautics: The company along with France based Safran will be jointly develop engines for military helicopters. The new joint venture will develop and produce engines in India. The engines will be used in multi-role helicopters and the deck based ones used by the Indian Navy and the coast guard.

Bandhan Bank: The bank’s loans and advances rose 20% YoY to Rs 96,649 crore in quarter from April to June. Deposits also grew 20% to Rs 93,057 crore. CASA ratio stood at 43.2% on June 30.

 Zydus Lifesciences: The company has launched Sitaglyn and Siglyn (Sitagliptin), for the management of Type 2 diabetes at a 60% low cost than the originator.

Linde India: The company inaugurated its first-ever women operated Packaged Gas Plant in Trichy.

Indian Overseas Bank: The bank raised MCLR by 10 basis points across tenors effective from July 10.

PowerGrid: The company has been declared as the successful bidder under Tariff based competitive bidding to build the project comprises establishment of two 400kV DIC

Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL